Markets

Verona Pharma prices IPO at $13.50

Verona Pharma, which is developing inhaled treatments for respiratory diseases, raised $78 million by offering 5.8 million shares at $13.50, in line with the expected price of $13.49. Verona Pharma plans to list on the Nasdaq under the symbol VRNA. Jefferies and Stifel acted as lead managers on the deal.

The article Verona Pharma prices IPO at $13.50 originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

VRNA

Other Topics

IPOs

Latest Markets Videos

    Renaissance Capital

    Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

    Learn More